Children's Oncology Group's 2023 blueprint for research: Liver tumors

• Published in: Pediatric blood & cancer Vol. 70; no. S6; pp. e30576 - n/a
• Main Authors: O'Neill, Allison F., Meyers, Rebecka L., Katzenstein, Howard M., Geller, James I., Tiao, Greg M., López‐Terrada, Dolores, Malogolowkin, Marcio
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2023
• Subjects: Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - therapy; Child; Combined Modality Therapy; Hematology; hepatoblastoma; Hepatoblastoma - pathology; Hepatoblastoma - therapy; hepatocellular; Hepatocellular carcinoma; Humans; international; liver; Liver cancer; Liver Neoplasms - pathology; Liver Neoplasms - therapy; Malignancy; Oncology; pediatric; Pediatrics; Prospective Studies; Tumors; hepatoblastoma; international; liver; hepatocellular; pediatric
• ISSN: 1545-5009; 1545-5017; 1545-5017
• DOI: 10.1002/pbc.30576

Liver tumors account for approximately 1%–2% of all pediatric malignancies, with the two most common tumors being hepatoblastoma (HB) and hepatocellular carcinoma (HCC). Previous Children's Oncology Group studies have meaningfully contributed to the current understanding of disease pathophysiology and treatment, laying groundwork for the ongoing prospective international study of both HB and HCC. Future work is focused on elucidating the biologic underpinnings of disease to support an evolution in risk categorization, advancements in the multidimensional care required to treat these patients, and the discovery of novel therapies.